Bio-Techne CEO Chuck Kummeth plans to retire by June 30, 2024; board begins successor search

BIO-TECHNE Corp

Revenue grew from $311M in FY2013 to $1.1B in FY2022 (CAGR >15%); employees grew from 800 to 3,000+.
Kummeth to receive 150k performance-vesting stock options for FY2023 and another 150k for FY2024, plus a $5M RSU award vesting over three years.
No base salary increase; bonus target remains at 160% of salary. Kummeth will stay on as CEO during the two-year transition.
Board evaluating internal and external CEO candidates; Kummeth is expected to remain on the board after retirement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Chuck Kummeth

Chief Executive Officer

TECH · BIO-TECHNE Corp

Effective: 2024-06-30
Filed: August 5, 2022, 7:59 PM ET

On August 4, 2022, Bio-Techne Corporation (the “Company”) announced Chuck Kummeth’s plan to retire from his position as Chief Executive Officer effective June 30, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chuck Kummeth departed as Chief Executive Officer at BIO-TECHNE Corp.

Action: retire
Role: Chief Executive Officer

Exact text from the filing

On August 4, 2022, Bio-Techne Corporation (the “Company”) announced Chuck Kummeth’s plan to retire from his position as Chief Executive Officer effective June 30, 2024

View on SEC.gov

BIO-TECHNE Corp filing history →

Source: SEC EDGAR

accession 0001558370-22-012336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.